Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice.

Find more on Medicine Matters diabetes

This content was originally published on Medicine Matters diabetes (https://diabetes.medicinematters.com) on April 15, 2019.